Genomed Spólka Akcyjna (WSE:GEN)

Genomed Spólka Akcyjna Income Statement

Financials in millions PLN. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	23.01	22.48	20.46	19.89	18.75
Revenue Growth (YoY)	2.34%	9.88%	2.84%	6.08%	-4.67%
Cost of Revenue	8.52	8.37	8.28	7.34	6.89
Gross Profit	14.49	14.11	12.18	12.55	11.87
Selling, General & Admin	11.89	11.48	10.42	10.11	10.17
Other Operating Expenses	0.66	0.76	0.67	0.34	0.52
Operating Expenses	13.29	12.86	11.82	11.21	11.4
Operating Income	1.2	1.24	0.36	1.34	0.47
Interest Expense	-0	-0	-0	-0	-0
Interest & Investment Income	0	0	0	-	-
Other Non Operating Income (Expenses)	0.01	-0.19	0.01	-0	-0.06
EBT Excluding Unusual Items	1.21	1.05	0.37	1.33	0.41
Pretax Income	1.21	1.05	0.37	1.33	0.41
Income Tax Expense	0.1	0.13	0.03	0.09	-0
Net Income	1.11	0.93	0.34	1.24	0.41
Net Income to Common	1.11	0.93	0.34	1.24	0.41
Net Income Growth	19.67%	174.07%	-72.70%	200.29%	-58.85%
Shares Outstanding (Basic)	1	1	1	1	1
Shares Outstanding (Diluted)	1	1	1	1	1
EPS (Basic)	0.84	0.70	0.26	0.94	0.31
EPS (Diluted)	0.84	0.70	0.26	0.94	0.31
EPS Growth	19.67%	174.07%	-72.70%	200.29%	-58.85%
Free Cash Flow	-0.03	1.76	-0.6	1.7	0.88
Free Cash Flow Per Share	-0.02	1.33	-0.46	1.28	0.67
Gross Margin	62.98%	62.75%	59.52%	63.09%	63.27%
Operating Margin	5.22%	5.53%	1.74%	6.72%	2.49%
Profit Margin	4.82%	4.12%	1.65%	6.22%	2.20%
Free Cash Flow Margin	-0.12%	7.84%	-2.94%	8.52%	4.71%
EBITDA	1.95	1.85	1.08	2.1	1.17
EBITDA Margin	8.45%	8.24%	5.27%	10.57%	6.26%
D&A For EBITDA	0.74	0.61	0.72	0.77	0.71
EBIT	1.2	1.24	0.36	1.34	0.47
EBIT Margin	5.22%	5.53%	1.74%	6.72%	2.49%
Effective Tax Rate	8.41%	11.94%	8.39%	7.11%	-
Revenue as Reported	23.01	22.48	20.46	19.89	18.75

Source: S&P Global Market Intelligence. Standard template. Financial Sources.